Search Medical Condition
Please enter condition
Please choose location from dropdown

Quimper cedex, France Clinical Trials

A listing of Quimper cedex, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (58) clinical trials

Cost Evaluation of Venous Leg Ulcers Management

The purpose of this study is to evaluate direct costs of Venous Leg Ulcers management when two different compression systems are used. Micro-costing during the study will bring direct costs which include nurse and physician time, dressings and bandages. Perspective of costs will be Public Health Insurance. Time horizon will ...

Phase N/A

0.0 miles

Learn More »

A Phase III of ADT + Docetaxel +/- Local RT +/- Abiraterone Acetate in Metastatic Hormone-na ve Prostate Cancer

Eligible patients can be randomize in the trial after his consent form has been signed, and after all inclusion and non-inclusion criteria have been checked. The randomisation will result in the allocation of arm A (ADT +docetaxel), arm B (ADT +docetaxel +Abiraterone), arm C (ADT +docetaxel +radiotherapy) or arm D ...

Phase

0.0 miles

Learn More »

Prospective Single-arm Multi Centre Observations Ultimaster Des Registry

All consecutive patients suitable for treatment with DES according to hospital routine practice in centres across the world that agree to participate in the e-ULTIMASTER registry will be treated with Ultimaster DES. Secondary objectives Evaluation of worldwide utilization of DES, Detection of rare events in representative patient population, identification of ...

Phase N/A

0.0 miles

Learn More »

Pregnancy Environment and Newborn Malformations

Population based case-control study: 2 controls per case will be included, corresponding to the first 2 births without congenital anomalies, with same sex and same birth place, following the case. INVESTIGATION METHODOLOGY : All maternity in Brittany were proposed to participate. In each maternity, the referent practitioner informs the parents ...

Phase N/A

0.0 miles

Learn More »

Six Years of Follow-up After Idiopathic Venous Throbmoembolism

Beyond the first 6 months of anticoagulation, patients with a first episode of unprovoked venous thromboembolism have a high risk of recurrence after stopping anticoagulations (about 10% at one year and 30% at 5 years). Extending anticoagulant therapy for an additional 18 months is associated with a major reduction of ...

Phase N/A

0.0 miles

Learn More »

Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease

This prospective randomized trial aims to evaluate the feasibility, risk and benefit of the discontinuation of immunosuppressive maintenance treatments in AAV (Antineutrophil Cytoplasmic Autoantibodies (ANCA)-associated vasculitis) patients who have reached ESRD (end-stage renal disease). Our hypothesis is that discontinuation of immunosuppressive therapy in AAV patients with ESRD will not expose ...

Phase

0.0 miles

Learn More »

Therapeutic Hypothermia in "Expanded Criteria" Brain-dead Donors and Kidney-graft Function

Each year, only one third of patients registered on the waiting list receive a kidney transplant. Numerous paths are being explored with the aim of reversing this shortage. The first is to increase the number of organs by developing harvesting from donors in a state of brain-death (BD) termed "expanded ...

Phase N/A

0.0 miles

Learn More »

Study of Programm Interest 'Bouge' to Improve the Daily Physical Activity at the Pregnant Women.

Controlled, randomized, open, prospective, multicentric study, 250 pregnant patients aged between 18 and more, with 14 weeks of amenorrhea, possessing a smartphone, will be recruited and randomized into two groups: 125 in the control group (smartphone application "placebo" = number of steps) 125 will be equipped with the application "Bouge" ...

Phase N/A

0.0 miles

Learn More »

A Study to Provide Complementary Efficacy Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting

This national, open-label study is designed to give complementary efficacy, safety and patient reported outcomes (PROs) data in participants with active relapsing forms of MS. Participants will receive a maximum of 2 treatment cycles of ocrelizumab infusions: an initial dose of two 300 milligram (mg) infusions separated by 14 days ...

Phase

0.0 miles

Learn More »